<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Meaningful Upcoming News-Flow]]></title><description><![CDATA[<p dir="auto">Meaningful Upcoming News-Flow<br />
Ofatumumab<br />
Phase II B-CLL data Japan, H1 2011<br />
Phase II DLBCL data, H2 2011<br />
Phase I/II RA sc data, H1 2011<br />
New Phase II MS sc trial, mid 2011<br />
Additional trials; <a href="http://ClinicalTrials.gov" rel="nofollow ugc">ClinicalTrials.gov</a><br />
Sales updates, quarterly<br />
Zalutumumab<br />
Partnership progress, H1 2011<br />
Daratumumab<br />
Phase I/II MM data, 2011<br />
New Phase I/II combi, H2 2011<br />
Minnesota facility sale progress<br />
Partnered programs progress<br />
New studies<br />
Next generation technologies<br />
Advancement DuoBodyTM &amp; ADC<br />
New Partnerships</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/448323/meaningful-upcoming-news-flow</link><generator>RSS for Node</generator><lastBuildDate>Sat, 20 Jun 2026 21:54:07 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/448323.rss" rel="self" type="application/rss+xml"/><pubDate>Sun, 06 Feb 2011 22:45:33 GMT</pubDate><ttl>60</ttl></channel></rss>